Indivior Pharmaceuticals (INDV) Cash from Operations (2024 - 2026)

Indivior Pharmaceuticals' Cash from Operations history runs 3 years deep, the most recent figure standing at 9000000.0 for Q1 2026.

• On a quarterly basis, Cash from Operations fell 112.0% year-over-year to 9000000.0 in Q1 2026; TTM through Mar 2026 was 111000000.0, a 175.0% decrease from a year earlier, with the FY2025 full-year figure at 27000000.0, down 175.0% from the prior year.
• Cash from Operations grew to 9000000.0 in Q1 2026 per INDV's latest filing, from 221000000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 158000000.0 in Q2 2025 and bottomed at 221000000.0 in Q4 2025.
• The 3-year median for Cash from Operations is 9000000.0 (2026), against an average of 0.0.
• Biggest YoY gain for Cash from Operations was 302.7% in 2025; the steepest drop was 2050.0% in 2025.
• Year by year, Cash from Operations stood at 17000000.0 in 2024, then tumbled by 1200.0% to 221000000.0 in 2025, then soared by 95.93% to 9000000.0 in 2026.
• Per Business Quant, the three latest INDV Cash from Operations figures stand at 9000000.0 (Q1 2026), 221000000.0 (Q4 2025), and 39000000.0 (Q3 2025).